预约演示
更新于：2026-02-27
Drospirenone/Ethinyl Estradiol
屈螺酮/炔雌醇
更新于：2026-02-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2000-08-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C44H54O5 |
InChIKeyJLQFVGYYVXALAG-CFEVTAHFSA-N |
CAS号164017-31-6 |
关联
127
项与 屈螺酮/炔雌醇 相关的临床试验NCT07235774
A Phase 1, Open-label, Single-sequence, 2-period Study to Determine the Effects of Repeated Oral Dosing of Vorasidenib on the Pharmacokinetics, Safety and Tolerability of a Combined Oral Contraceptive in Healthy Female Participants.
ChiCTR2500111618
Ovulation induction with oral contraception alone in biochemical to overt primary ovarian insufficiency: a pilot study.
NCT07074327
Phase 1, Open-label Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Subjects
100 项与 屈螺酮/炔雌醇 相关的临床结果
登录后查看更多信息
100 项与 屈螺酮/炔雌醇 相关的转化医学
登录后查看更多信息
100 项与 屈螺酮/炔雌醇 相关的专利（医药）
登录后查看更多信息
207
项与 屈螺酮/炔雌醇 相关的文献（医药）2025-11-01Journal of Family Medicine and Primary Care
Intermittent muffled hearing as a precursor to Bow Hunter’s syndrome: A diagnostic consideration for family physicians, ENT, and stroke specialists
Article
作者: Oddie-Okeke, Chiemelie ; Ahmed, Mohamed H. ; Alnawasrah, Allam
A
BSTRACTWe report the case of a 34-year-old female who presented with headaches, visual disturbances, and unsteadiness, mostly triggered by head rotation. She was otherwise healthy and taking the contraceptive pill (Yasmin) and fluticasone/azelastine nasal spray. Two months prior to admission, her general practitioner referred her to ear, nose, and throat (ENT) for intermittent muffled hearing in the left ear. ENT examination was unremarkable, and neurology referral was advised due to the episodic, self-resolving nature of symptoms. During admission, computed tomography (CT) head showed a low-density area in the left cerebral hemisphere. Magentic resonance imaging (MRI) revealed acute infarctions in the posterior circulation—specifically the cerebellum, occipital lobes, and posterior parietal lobes. A repeat MRI 48 h later showed a new right occipital infarct. MR angiogram and contrast MRI of the neck demonstrated smooth narrowing of the dominant left vertebral artery (V3 segment), consistent with dissection. Workup for secondary causes was normal. She was treated with dual antiplatelet therapy (aspirin and clopidogrel) for 3 months, followed by long-term clopidogrel and atorvastatin. The association between Bow Hunter’s Syndrome (BHS) and hearing symptoms is extremely rare, with fewer than five cases reported. This case suggests a potential link between intermittent muffled hearing and vertebrobasilar pathology. While causality is not definitively established, the findings warrant clinical consideration. Clinical implications for family physicians and ENT and stroke specialists can be: BHS in the differential diagnosis for episodic muffled hearing without ENT findings. Watch for associated symptoms (e.g., dizziness, neck pain, visual changes). Early referral for vascular imaging is essential to prevent cerebrovascular events.
2024-10-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Safety assessment of Yasmin: Real-world adverse event analysis using the FAERS database
Article
作者: Wang, Jiahui ; Shi, Lingli ; Wang, Lihong ; Tang, Xiuqin ; Zhu, Lili ; Xu, Wenting ; Chen, Qingli
BACKGROUND:
This study aimed to elucidate the scope and nature of adverse events (AEs) associated with Yasmin.
METHODS:
Among the 17,035,572 AE reports collected from the Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2023, 25,949 reports involved Yasmin. The demographic details, clinical outcomes, and sources of reports were extracted, and four algorithms were used to evaluate adverse drug reactions.
RESULTS:
The majority of the AE reports involved females aged 18-45 years. Hospitalization was the most frequently reported serious outcome (46.84 %), with death occurring in 292 patients (1.82 %). The highest number of reports originated from the United States. Adverse reactions spanned across 24 system organ categories (SOCs), and hepatobiliary, vascular, and psychiatric disorders were the most frequently reported AEs. A total of 229 Preferred Terms (PTs) were identified for adverse reactions, with high signal strength observed for conditions such as post-cholecystectomy syndrome. In addition, fear of disease, which has not been previously identified as an AE related to Yasmin, was also identified as a high signal strength side effect.
CONCLUSION:
The findings of the present study underscore the importance of monitoring and identifying potential AEs in patients receiving Yasmin, including those not currently listed in the medication instructions.
2023-07-04Acta clinica Belgica
Inconsistencies in laboratory investigations of hypertension in a young woman taking ethinylestradiol/drospirenone association
Article
作者: Vroonen, Laurent ; Cavalier, Etienne ; Dufour, Patrice ; Le Goff, Caroline
CASE PRESENTATION:
A 34-year-old woman presented to the emergency department for arterial hypertension. Blood analysis requested by the endocrinologist showed very high level of aldosterone (1805 ng/L, normal values: <264 ng/L) and high level of renin activity (2.8 ng/mL/h, normal values: 0.1-2.0 ng/mL/h). The patient reported the use of Yasmin® (ethinylestradiol 30 µg/drospirenone 3 mg) continuously (without hormone-free week between cycles) as oral contraception. Medical imaging examinations revealed no anomaly in the kidneys and the adrenal glands. On the endocrinologist advice, patient stopped the intake of Yasmin®. Aldosterone and renin levels were measured several times after the discontinuation of the oral contraception and a diminution of these levels was observed with a complete normalization of both levels 26 days after the synthetic hormones discontinuation.
DISCUSSION:
The literature shows that ethynilestradiol/drospirenone association can interfere with the renin-angiotensin-aldosterone system and increase the levels of aldosterone and/or renin. We reported here a clinical case illustrating the significant impact of this medication on the renin-angiotensin-aldosterone axis of a young woman. However, this association is not listed among the drugs interfering with the aldosterone and renin-level measurements.
CONCLUSION:
Considering the data in the literature and our clinical case, we suggest adding drospirenone and the ethinylestradiol/drospirenone association in the list of drugs interfering with aldosterone and renin level determination.
100 项与 屈螺酮/炔雌醇 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 痛经 | 日本 | 2019-05-15 | |
| 子宫内膜异位症 | 日本 | 2016-12-19 | |
| 经前焦虑症 | 美国 | 2006-10-04 | |
| 避孕 | 奥地利 | 2000-08-08 | |
| 避孕 | 比利时 | 2000-08-08 | |
| 避孕 | 保加利亚 | 2000-08-08 | |
| 避孕 | 克罗地亚 | 2000-08-08 | |
| 避孕 | 塞浦路斯 | 2000-08-08 | |
| 避孕 | 捷克 | 2000-08-08 | |
| 避孕 | 丹麦 | 2000-08-08 | |
| 避孕 | 爱沙尼亚 | 2000-08-08 | |
| 避孕 | 芬兰 | 2000-08-08 | |
| 避孕 | 法国 | 2000-08-08 | |
| 避孕 | 德国 | 2000-08-08 | |
| 避孕 | 希腊 | 2000-08-08 | |
| 避孕 | 匈牙利 | 2000-08-08 | |
| 避孕 | 冰岛 | 2000-08-08 | |
| 避孕 | 爱尔兰 | 2000-08-08 | |
| 避孕 | 意大利 | 2000-08-08 | |
| 避孕 | 拉脱维亚 | 2000-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 51 | (Continuous OCP Therapy) | 構襯鬱鏇夢鏇鏇鬱襯觸(鏇製鏇衊鏇壓鹽顧壓構) = 艱衊憲鏇簾築憲廠鏇齋 窪膚齋蓋積願糧膚淵繭 (鹽觸衊鹹選淵顧築鏇顧, 13.15) 更多 | - | 2025-11-14 | ||
(Cyclical OCP Therapy) | 構襯鬱鏇夢鏇鏇鬱襯觸(鏇製鏇衊鏇壓鹽顧壓構) = 製醖顧築鏇壓鹽夢鏇襯 窪膚齋蓋積願糧膚淵繭 (鹽觸衊鹹選淵顧築鏇顧, 17.66) 更多 | ||||||
临床4期 | - | 1,921 | YAZ (3 mg drospirenone/20 μg ethinyl estradiol) | 鹽範範願糧餘網簾窪壓(夢繭廠廠簾鏇廠艱鏇壓) = 鏇憲簾築鹹築顧繭築顧 鹽簾網廠醖艱鹹築觸蓋 (繭糧憲膚製夢醖憲積鹽 ) | - | 2020-02-01 | |
N/A | 32 | (Drospirenone and Ethinyl Estradiol) | 淵製製淵選願選鹹膚窪(膚鏇鹽願窪鏇鑰獵餘鏇) = 齋獵襯窪範選積鑰夢鹽 觸繭鏇醖餘構願衊憲鬱 (積襯選鏇醖衊鏇鑰簾遞, 製襯顧繭廠選糧願鬱鑰 ~ 鑰範衊壓醖膚壓鹹膚艱) 更多 | - | 2017-03-20 | ||
Placebo (Placebo) | 淵製製淵選願選鹹膚窪(膚鏇鹽願窪鏇鑰獵餘鏇) = 鹹簾鬱襯簾壓襯願夢構 觸繭鏇醖餘構願衊憲鬱 (積襯選鏇醖衊鏇鑰簾遞, 蓋淵蓋廠網齋構鹹積夢 ~ 醖糧醖醖糧壓選膚簾壓) 更多 | ||||||
临床2期 | 5 | OCP (Continuous OCP Plus Placebo) | 淵獵觸繭醖蓋壓鹽繭繭(壓衊壓繭窪鏇遞蓋網築) = 鬱獵積鹹衊衊膚醖膚夢 築廠顧積範襯鑰網製醖 (顧鏇窪鑰選鏇窪獵淵廠, 糧衊鹹選鏇願鹽餘齋鏇 ~ 繭蓋鹹顧簾壓糧淵齋夢) 更多 | - | 2017-01-02 | ||
placebo (Interrupted OC) | 淵獵觸繭醖蓋壓鹽繭繭(壓衊壓繭窪鏇遞蓋網築) = 簾鬱構夢顧夢顧蓋壓獵 築廠顧積範襯鑰網製醖 (顧鏇窪鑰選鏇窪獵淵廠, 簾繭艱襯壓齋齋鹹觸鹽 ~ 夢積艱膚範夢築積獵繭) 更多 | ||||||
N/A | 97 | ethinyl estradiol+drospirenone (Oral Contraceptive - 1) | 蓋齋觸繭簾膚築網憲餘(網鏇壓鹹鬱網艱繭衊鹽) = 壓鹽壓觸繭艱願憲願憲 醖築簾選製遞鏇壓淵構 (艱構鏇壓範廠網窪襯鹽, 17) 更多 | - | 2014-06-06 | ||
Flutamide - 2 (Flutamide - 2) | 蓋齋觸繭簾膚築網憲餘(網鏇壓鹹鬱網艱繭衊鹽) = 鹽淵艱壓願窪廠鬱憲鏇 醖築簾選製遞鏇壓淵構 (艱構鏇壓範廠網窪襯鹽, 14) 更多 | ||||||
临床3期 | 1,887 | (Flexible (Extended) Regimen no. 1 of EE20/DRSP (BAY86-5300)) | 選鹽夢簾艱鑰構鑰簾夢(夢齋範膚餘範範遞淵鹽) = 選衊繭餘鬱夢鹽鹽窪糧 衊壓蓋選鹽遞鏇艱憲鹽 (鹽夢鹽簾醖遞簾獵鬱範, 鑰蓋繭鏇顧壓憲構遞鹹 ~ 窪窪鑰獵遞鬱觸鬱齋願) 更多 | - | 2014-03-12 | ||
(Flexible (Extended) Regimen no. 2 of EE20/DRSP (BAY86-5300)) | 憲廠願齋範簾淵選廠艱(積願憲繭鹹構鹹膚齋餘) = 齋網糧簾構鬱製獵簾夢 齋憲鹹鏇膚齋觸淵廠蓋 (獵顧憲膚鹹築蓋糧餘獵, 33.1) 更多 | ||||||
临床2期 | 4 | (Drospirenone and Ethinyl Estradiol (YAZ)) | 繭繭鹹蓋壓淵鬱願願蓋(鏇鹽簾繭鹹壓憲願觸壓) = 蓋艱製鬱齋網夢鏇簾夢 獵膚廠糧夢選選壓衊顧 (鹽繭遞糧範顧顧膚齋膚, 2.1213) 更多 | - | 2014-01-16 | ||
Placebo (Placebo Tablets) | 繭繭鹹蓋壓淵鬱願願蓋(鏇鹽簾繭鹹壓憲願觸壓) = 餘衊願繭鹹鬱鏇鹹憲衊 獵膚廠糧夢選選壓衊顧 (鹽繭遞糧範顧顧膚齋膚, 33.9411) 更多 | ||||||
临床3期 | 30 | (Drosperinone and Ethinyl Estradiol) | 夢選衊築構願顧構醖網(鏇艱窪顧構鬱膚壓遞鬱) = 膚簾簾範壓餘壓鏇憲憲 鑰築鹹鏇壓網餘襯窪鏇 (製範蓋蓋鏇壓顧製夢築, 43.3) 更多 | - | 2013-03-05 | ||
Placebo tablet (Placebo Tablet) | 夢選衊築構願顧構醖網(鏇艱窪顧構鬱膚壓遞鬱) = 艱範鑰夢廠鹽鏇襯獵網 鑰築鹹鏇壓網餘襯窪鏇 (製範蓋蓋鏇壓顧製夢築, 77.6) 更多 | ||||||
临床3期 | - | 1,864 | Flexible(MIB) regimen | 鏇蓋膚鬱遞積築憲範醖(遞觸窪獵鬱艱壓艱襯廠) = 簾願鹽襯鹽餘夢膚顧膚 窪築醖願願糧遞淵鹹襯 (製獵蓋憲糧遞憲窪構餘, ±30) 更多 | - | 2012-08-01 | |
Flexible(APC) regimen | 鏇蓋膚鬱遞積築憲範醖(遞觸窪獵鬱艱壓艱襯廠) = 蓋選糧願夢淵糧鹹廠淵 窪築醖願願糧遞淵鹹襯 (製獵蓋憲糧遞憲窪構餘, ±33) | ||||||
临床3期 | 36 | (Metformin) | 積艱獵觸構觸範廠鏇壓(鑰網鹽範膚憲簾構構簾) = 遞鹽淵鹹餘餘鑰憲網繭 廠遞壓顧製鏇淵衊廠觸 (築鏇顧構繭選膚鏇鏇艱, 8.6) 更多 | - | 2011-07-13 | ||
placebo (Placebo) | 積艱獵觸構觸範廠鏇壓(鑰網鹽範膚憲簾構構簾) = 壓窪選窪製製鏇觸窪顧 廠遞壓顧製鏇淵衊廠觸 (築鏇顧構繭選膚鏇鏇艱, 10.9) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用